M&A Deal Summary

AbbVie Acquires Allergan

On June 25, 2019, AbbVie acquired life science company Allergan for 63.0B USD

Acquisition Highlights
  • This is AbbVie’s 4th transaction in the Life Science sector.
  • This is AbbVie’s largest (disclosed) transaction.
  • This is AbbVie’s 4th transaction in the United States.
  • This is AbbVie’s 1st transaction in New Jersey.

M&A Deal Summary

Date 2019-06-25
Target Allergan
Sector Life Science
Buyer(s) AbbVie
Deal Type Add-on Acquisition
Deal Value 63.0B USD
Advisor(s) J.P. Morgan Securities LLC (Financial)
Wachtell, Lipton, Rosen & Katz LLP
Arthur Cox & Co. (Legal)

Target

Allergan

Parsippany, New Jersey, United States
website
Allergan plc (formerly Actavis Plc and initially known as Watson Pharmaceuticals, Inc.) is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.

Search 175,816 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AbbVie

North Chicago, Illinois, United States

website


Category Company
Founded 2012
SectorLife Science
Employees50,000
Revenue 56.2B USD (2021)
DESCRIPTION
Entrance to Abbvie's office in Lake Forest, Illinois.
Entrance to Abbvie's office in Lake Forest, Illinois.

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.


DEAL STATS #
Overall 4 of 7
Sector (Life Science) 4 of 7
Type (Add-on Acquisition) 3 of 6
State (New Jersey) 1 of 1
Country (United States) 4 of 5
Year (2019) 1 of 2
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-28 Stemcentrx

South San Francisco, California, United States

Stemcentrx develops therapies that aim to cure and significantly improve survival for cancer patients. The Company was formed in 2008 and is based South San Francisco, California.

Buy $5.8B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-15 Mavupharma

Kirkland, Washington, United States

Mavupharma is a biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. Mavupharma was founded in 2016 and is based in Kirkland, Washington.

Buy -